Grunenthal Logo

External Link

You are now leaving the Grünenthal website. You will be re-directed to an external website. Grünenthal accepts no responsibility for the content of other websites.

Quentin Le Masne de Chermont, Head of Corporate Strategy and Portfolio Management

Acquisition of Crestor™

Grünenthal acquired the European rights (excluding Spain and the UK) to Crestor™ (rosuvastatin) from AstraZeneca in February 2021.
Acquisition of Crestor™

This product is a statin, also known as a lipid-lowering medicine. It blocks an enzyme in the liver from causing the liver to make less cholesterol, while it also increases the uptake and breakdown of cholesterol by the liver. Crestor™ is used to treat blood lipid disorders and prevent cardiovascular events like heart attacks and strokes, which are among the most burdensome diseases in Europe1.

Crestor™ is approved as a lipid-regulating medicine in more than 100 countries. With this agreement, Grünenthal acquired the exclusive rights to market Crestor™ and its second brands in more than 30 European markets. The company will also take over bulk production and packaging for the defined markets by 2025.

1 Townsend N, Wilson L, Bhatnagar P et al. Cardiovascular disease in Europe: epidemiological update 2016. European Heart Journal. 2016;37: 3232-3245.

Further details on our company can be found in our annual report.

Get in touch

We are keen to hear new ideas and discover assets that are relevant to our business. If you are interested in partnering with us, get in touch.

Contact us

M-N/A-DE-01-23-0007